Nykode Enters New Phase With Regeneron Vaccine Pact
US Major Pays $30m Upfront And Takes Stake
Executive Summary
Regeneron is investing heavily to advance five vaccine programs with Nykode Therapeutics, the Norwegian company formerly known as Vaccibody.
You may also be interested in...
Roche Continues To Cast Its Collaborations Net Wide
The Swiss major gets around 3,000 proposals per year and has assembled a 120-strong team to sift through them and access the best science out there. Global head of pharma partnering James Sabry tells Scrip what Roche is looking for in a partner.
Deal Watch: Lilly Teams With Regor On Metabolic Disorders
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.